We are excited to discuss encouraging initial safety data from the first participant in our Phase 1/2 clinical trial of ...
BOSTON--(BUSINESS WIRE)--Ensoma, an in vivo hematopoietic stem cell (HSC) engineering company with a mission to advance the future of medicine through one-time therapies, today announced the closing ...
In recent years regenerative cell therapy utilizing the pluripotency of hESCs or iPSCs is gaining its ground and holds promise to outpace conventional treatment options for cardiac, kidney, liver, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results